OBJECTIVES: The primary objective was to evaluate the effect of omega-3 fatty acids (omega-3 FA) on matrix metalloproteinase-9 (MMP-9) production by immune cells in multiple sclerosis (MS). Quality of life, fatty acid levels, and safety were also evaluated. MATERIALS AND METHODS: Ten participants with relapsing-remitting MS (RRMS) received omega-3 FA supplementation (9.6g/day fish oil) in an open-label study. Participants were evaluated at four time points, baseline, after 1 month of omega-3 FA supplementation, after 3 months of omega-3 FA supplementation, and after a 3-month wash out. RESULTS: Immune cell secretion of MMP-9 decreased by 58% after 3 months of omega-3 FA supplementation when compared with baseline levels (p<0.01). This effect was coupled with a significant increase in omega-3 FA levels in red blood cell membranes. CONCLUSIONS: Omega-3 FA significantly decreased MMP-9 levels in RRMS and may act as an immune-modulator that has potential therapeutic benefit in MS patients.
OBJECTIVES: The primary objective was to evaluate the effect of omega-3 fatty acids (omega-3 FA) on matrix metalloproteinase-9 (MMP-9) production by immune cells in multiple sclerosis (MS). Quality of life, fatty acid levels, and safety were also evaluated. MATERIALS AND METHODS: Ten participants with relapsing-remitting MS (RRMS) received omega-3 FA supplementation (9.6g/day fish oil) in an open-label study. Participants were evaluated at four time points, baseline, after 1 month of omega-3 FA supplementation, after 3 months of omega-3 FA supplementation, and after a 3-month wash out. RESULTS: Immune cell secretion of MMP-9 decreased by 58% after 3 months of omega-3 FA supplementation when compared with baseline levels (p<0.01). This effect was coupled with a significant increase in omega-3 FA levels in red blood cell membranes. CONCLUSIONS:Omega-3 FA significantly decreased MMP-9 levels in RRMS and may act as an immune-modulator that has potential therapeutic benefit in MS patients.
Authors: E Waubant; D E Goodkin; L Gee; P Bacchetti; R Sloan; T Stewart; P B Andersson; G Stabler; K Miller Journal: Neurology Date: 1999-10-22 Impact factor: 9.910
Authors: M A Harris; R A Hansen; P Vidsudhiphan; J L Koslo; J B Thomas; B A Watkins; K G Allen Journal: Prostaglandins Leukot Essent Fatty Acids Date: 2001-07 Impact factor: 4.006
Authors: Clare L Curtis; Sarah G Rees; Chris B Little; Carl R Flannery; Clare E Hughes; Chris Wilson; Colin M Dent; Ivan G Otterness; John L Harwood; Bruce Caterson Journal: Arthritis Rheum Date: 2002-06
Authors: W I McDonald; A Compston; G Edan; D Goodkin; H P Hartung; F D Lublin; H F McFarland; D W Paty; C H Polman; S C Reingold; M Sandberg-Wollheim; W Sibley; A Thompson; S van den Noort; B Y Weinshenker; J S Wolinsky Journal: Ann Neurol Date: 2001-07 Impact factor: 10.422
Authors: M José Bagur; M Antonia Murcia; Antonia M Jiménez-Monreal; Josep A Tur; M Mar Bibiloni; Gonzalo L Alonso; Magdalena Martínez-Tomé Journal: Adv Nutr Date: 2017-05-15 Impact factor: 8.701